Michael Epstein
Michael Epstein
Achilles Theraputics
Verified email at
Cited by
Cited by
A robust model for read count data in exome sequencing experiments and implications for copy number variant calling
V Plagnol, J Curtis, M Epstein, K Mok, E Stebbings, S Grigoriadou, ...
Bioinformatics, 2012
Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer
C Fribbens, IG Murillas, M Beaney, S Hrebien, B O’Leary, L Kilburn, ...
Annals of Oncology 29 (1), 145-153, 2018
Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA
D Gale, ARJ Lawson, K Howarth, M Madi, B Durham, S Smalley, ...
PloS one 13 (3), e0194630, 2018
Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling
V Plagnol, S Woodhouse, K Howarth, S Lensing, M Smith, M Epstein, ...
PloS one 13 (3), e0193802, 2018
Isolation and comparative transcriptome analysis of human fetal and iPSC-derived cone photoreceptor cells
E Welby, J Lakowski, V Di Foggia, D Budinger, A Gonzalez-Cordero, ...
Stem Cell Reports 9 (6), 1898-1915, 2017
Capturing needles in haystacks: a comparison of B-cell receptor sequencing methods
RJM Bashford-Rogers, AL Palser, SF Idris, L Carter, M Epstein, ...
BMC immunology 15 (1), 1-9, 2014
Bayesian statistical inference in ion-channel models with exact missed event correction
M Epstein, B Calderhead, MA Girolami, LG Sivilotti
Biophysical journal 111 (2), 333-348, 2016
Revealing individual signatures of human T cell CDR3 sequence repertoires with Kidera factors
M Epstein, M Barenco, N Klein, M Hubank, RE Callard
PLoS One 9 (1), e86986, 2014
Bayesian approaches for mechanistic ion channel modeling
B Calderhead, M Epstein, L Sivilotti, M Girolami
In silico systems biology, 247-272, 2013
543 Sensitive quantification and tracking of the active components of a Clonal Neoantigen T cell (cNeT) therapy: From manufacture to peripheral circulation
S Turajlic, M Jamal-Hanjani, A Furness, R Plummer, J Cave, ...
Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021
Characterization of a novel clonal neoantigen reactive T cell (cNeT) product through a comprehensive translational research program
M Epstein, R Pike, E Leire, J Middleton, M Wileman, L Ouboussad, ...
Cancer Research 81 (13_Supplement), 1508-1508, 2021
427 Development of iPSC-derived cytotoxic CD8+ T-cells as the basis for innovative off-the-shelf cancer immunotherapies
R Tawo, F Bertrand, O Cypris, C Beuraud, P Hublitz, P Barron, S Pfänder, ...
Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023
1515 Gene edited iPSC-derived macrophages (iMACs) show increased phagocytosis in pre-clinical tumor models
K Haake, M Mirenda, Q Bernard, P Hublitz, L Gouxette, M Briscadieu, ...
Journal for ImmunoTherapy of Cancer 11 (Suppl 2), 2023
193 The Achilles VELOSTM Process 2 boosts the dose of highly functional clonal neoantigen-reactive T cells for precision personalized cell therapies
E Kotsiou, J Robinson, A Rogers, D Melandri, A Baker, AR Aragon, ...
Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021
Multicentre, prospective research protocol for development of a clonal neoantigen-reactive T cell therapy pipeline across multiple tumour types
M Grant, T Hou, F Kyle, FKK Miller, J Robinson, A Rogers, ...
HUMAN GENE THERAPY 32 (19-20), A20-A20, 2021
Isolating and characterising human cone photoreceptors for cell therapy
E Welby, V Di Foggia, J Lakowski, D Budinger, K Kruczek, M Hubank, ...
Conference on Changing the Face of Modern Medicine-Stem Cells and Gene Therapy, 2016
The system can't perform the operation now. Try again later.
Articles 1–16